CD44 and head and neck squamous cell carcinoma: Thus, despite the high prevalence of PD-L1 expression in HNSCC, the immune checkpoint inhibitors do not show satisfactory clinical response due to primary and adaptive resistance, including the immunosuppressive capabilities presented by CD44 + cells (Kok 2020).